Skip to main content
Fig. 6 | BMC Pulmonary Medicine

Fig. 6

From: Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds

Fig. 6

Effects of MEK162/BKM120 combination and BIBW2997/ARQ197 combination therapy on EGFR, MET, MAPK, and PI3K pathways. H1975 (A), H460 (B), and A549 (C) cells were treated with 1 μM MEK162/5 μM BKM120 combination and 1 µM BIBW2992/2 µM ARQ197 combination for 48 h. Control cells were treated with 0.05% DMSO. Whole cell lysates were collected for Western blot analysis. β-actin protein levels were evaluated as loading controls

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us